|| List of recent Analogue-related patents
| Flexible carbohydrate-bearing polymer|
A sensor for the detection or measurement of a carbohydrate analyte in fluid comprises components of a competitive binding assay the readout of which is a detectable or measurable optical signal retained by a material that permits diffusion of the analyte but not the assay components, the assay components comprising: a carbohydrate binding molecule labelled with one of a proximity based signal generating/modulating moiety pair; and a carbohydrate analogue capable of competing with the analyte for. Binding to the carbohydrate binding molecule, the carbohydrate analogue being a flexible water-soluble polymer comprising: polymerized or co-polymerised residues of monomer units, the monomer unit residues bearing pendant carbohydrate or carbohydrate mimetic moieties and pendant moieties which are the other of the proximity based signal generating/modulating moiety pair..
| Etomidate analogues with improved pharmacokinetic and pharmacodynamic properties|
Where r1 is l1c(o)ot or l1c(o)ol2c(o)ot; r2 is a substituted or unsubstituted c1-c10 alkyl, c2-c10 alkenyl, or c2-c10 alkynyl, or r1; n is an integer from 0 to 5; each r3 is independently halogen or r2; l1 and l2 are each independently a bond, a substituted or unsubstituted c1-c10 alkylene, c2-c10 alkenylene, or c2-c10 alkynylene; and t is h, a substituted or unsubstituted c1-c10 alkyl, c2-c10 alkenyl, or c2-c10 alkynyl, nitrophenol, or cyclopropyl. The invention is also directed to a pharmaceutical composition comprising a compound according to formula (i) and a pharmaceutically acceptable carrier, and to methods for providing anesthesia in mammals by administering such a pharmaceutical composition..
| Methods of treating complications and disorders associated with g-csf administration|
The present embodiments relate to novel uses of mpo inhibitors and inhibitors of mpo and e-selectin binding. In some embodiments, methods are provided for treating g-csf-induced vascular complications and associate tissue injury comprising administering to a subject in need thereof a compound that inhibits e-selectin receptor/ligand interaction or inhibits mpo activity.
| Apparatus, method and system for providing new communication services over existing wiring|
The invention provides apparatus for providing a next-generation communication system over existing wiring. In one form the apparatus includes an input to receive broadband signals carrying next-generation communication data, a processor to extract the next-generation communication data from the broadband signals and a converter to convert the next-generation communication data into analogue telephone signals.
| Microwave induced single step green synthesis of some novel 2-aryl aldehydes and their analogues|
A microwave-induced process for the preparation of 2-aryl and 2,2-diaryl aldehydes and analogues wherein halohydrin formation and subsequent rearrangement to 2-aryl aldehydes from corresponding aryl alkanols occurs without formation of an intermediate epoxide or use of transition metal catalysts or lewis acids/bases.. .
|Radioactive cesium adsorbent, method for producing the same, and method for removing radioactive cesium in environment with said adsorbent|
The present invention relates to a radioactive cesium adsorbent, a method for producing the same, and a method for decontaminating the environment from radioactive cesium with the adsorbent. The radioactive cesium adsorbent of the present invention includes a hydrophilic fiber substrate supporting a prussian blue analogue, in particular, prussian blue, and the prussian blue analogue is immobilized in the inside of the fibers..
|Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis|
A method for obtaining improved bone quality in a vertebrate, including mammal and bird, the method comprising administering to a vertebrate, including mammal and bird, in a sufficient amount and/or at a sufficient rate to enable a desired effect, glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof. Also contemplated is a method for modulating bone quality in a vertebrate, including mammal and bird, comprising administering to the vertebrate, including mammal and bird, in the need thereof, glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof, for modulating the bone quality as well as a compositions for use in treatment..
|Composition for eyelash growth|
The present invention relates to a pharmaceutical or cosmetic composition and a method for promoting eyelash growth, wherein nipradilol or pharmaceutically or cosmetically acceptable salts thereof are used as active ingredients. The composition of the invention may comprise prostaglandin f2α analogues..
|New family of analogues and nadp+ or nadph, their preparation and their application in therapeutics|
A new family of analogues of nadp+ or nadph, their preparation and their application in therapeutics.. .
|Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system|
This invention relates to novel compounds suitable for labelling by 18f and the corresponding 18f labelled compounds themselves, 19f-fluorinated analogues thereof and their use as reference standards, methods of preparing such compounds, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (pet).. .
|Alignment of non-synchronous data streams|
An apparatus for aligning non-synchronous input data streams received in the apparatus, the apparatus comprising an analogue to digital converter arrangement for digitising the data streams into a plurality of sequences of samples; and a synchronisation processing arrangement for generating alignment pulses for each sequence of the plurality of sequences of samples, for arranging each sequence of samples with respect to the alignment pulses for the sequence and for synchronisation the delivery of said plurality of sequences of samples to a common processor with respect to the respective alignment pulses. The synchronisation processing arrangement may comprise a processing chain for each antenna feed of said plurality of antenna feeds and each processing chain may comprise an alignment pulse generator for generating an alignment pulse for the sequence of samples corresponding to the processing chain.
An integrated-circuit, continuous-time, sigma-delta analogue-to-digital converter has a single-ended analogue input, a converter reference input, and a ground connection. The converter has a resistor-capacitor integrator arranged to receive the single-ended analogue input.
|Inferential coriolis mass flowmeter|
The present invention relates to an inferential coriolis mass flowmeter characterized by: a power supply (10);a pressure sensor (11) connected to the power supply (10) and a tube of fluid; a current to voltage converter (13) connected to the pressure sensor (11) for converting a current signal from the pressure sensor (11) to a voltage signal; a controller unit (20) including an analogue to digital converter (21) connected to the current to voltage converter (13) for converting analogue signal from the current to voltage converter (13) to a digital signal, and a microprocessor (22) for processing the digital signal from the analogue to digital converter (21) to determine the mass flowrate of the fluid, wherein said microprocessor (22) is embedded with an algorithm to determine the mass flowrate of a fluid according to equation (1): y=0.002x4−0.0218x3+0.0865x2+0.8769x+0.0846 ; a display panel (14) connected to the microprocessor (22); and a transmission circuit (15) connected to the microprocessor (22).. .
|Asymetric synthesis of norcantharidin analougus by alkynylation of oxabenzonorbornadienes and their anticancer activities|
The present invention relates to a type of norcantharidin analogues and a method to synthesis such norcantharidin analogues by transition metal-catalyzed alkynylation of 7-oxabenzonorbornadienes. The present invention also relates to the use of such norcantharidin analogues in manufacture of a medicament for the treatment of cancer tumors..
|Preparation of (r,r)-fenoterol and (r,r)-or (r,s)-fenoterol analogues and their use in treating congestive heart failure|
This disclosure concerns the discovery of (r,r)- and (r,s)-fenoterol analogues which are highly effective at binding β2-adrenergic receptors. Exemplary chemical structures for these analogues are provided.
|Oxanorbornadiene derivatives and their anticancer activities|
The present invention relates to chemical entities originated from natural sources and further synthesized for therapeutic uses. More particularly, the present invention relates to norcantharidin analogues synthesized by a transition metal-catalyzed alkynylation of oxanorbornadiene derivatives and their antitumor effects..
|Treatments for diabetes mellitus and obesity|
Methods of treatment in subjects suffering from diabetes mellitus or obesity are provided. The methods comprise the step of administering an active agent directly to the small intestine in the subject.
|Methods of producing 6-carbon chemicals via coa-dependent carbon chain elongation associated with carbon storage|
This document describes biochemical pathways for producing adipic acid, caprolactam, 6-aminohexanoic acid, 6-hydroxyhexanoic acid, hexamethylenediamine or 1,6-hexanediol by forming two terminal functional groups, comprised of carboxyl, amine or hydroxyl groups, in a c6 aliphatic backbone substrate. These pathways, metabolic engineering and cultivation strategies described herein rely on coa-dependent elongation enzymes or analogues enzymes associated with the carbon storage pathways from polyhydroxyalkanoate accumulating bacteria..
|Bisacodyl and its analogues as drugs for use in the treatment of cancer|
The present invention provides compounds having the formula a: (a) or pharmaceutically acceptable salt thereof, wherein w, r1, r2 and r5 are as defined in classes and subclasses herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as cytotoxic agents towards proliferating and/or quiescent cancer stem cells, and thus are useful, for example, for the treatment of cancer.. .
|Glycolipids and analogues thereof as antigens for nkt cells|
This invention relates to immunogenic compounds which serve as ligands for nkt (natural killer t) cells and to methods of use thereof in modulating immune responses.. .
|Tacrolimus for improved treatment of transplant patients|
An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time.
|Heterocyclyl pyrimidine analogues as jak inhibitors|
Wherein x1 to x5, z1 to z3, y0, ry1, ry2 and r have the meaning as cited in the description and the claims. Said compounds are useful as jak inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases.
|Device and methods for detecting analytes in saliva|
The invention provides a device for detecting drugs of abuse or other compounds in saliva. The invention thus provides a device for detecting the presence of one or more analytes in a saliva sample, comprising: (a) one or more pre-treatment regions for specifically or non-specifically removing at least a part of the fraction of the saliva sample interfering with detection of the one or more analytes; and (b) a detection region comprising a biosensor surface, the surface comprising: molecules capable of specifically binding the one or more analytes; or the one or more analytes and/or analyte analogues..
|Rf transmitter, integrated circuit device, wireless communication unit and method therefor|
A radio frequency (rf) transmitter includes a power amplifier comprising a plurality of power amplifier cells. At least one digital signal processing module of the rf transmitter is operably coupled to the power amplifier and comprises at least one digital pre-distortion component arranged to apply at least one digital pre-distortion codeword to the plurality of power amplifier cells, wherein the at least one digital pre-distortion codeword is applied to at least one of the plurality of power amplifier cells via a digital filter.
|Radio frequency communication|
An analogue modem circuit and carrier recovery method are disclosed for use between an rf receiver and a digital modem circuit configured for receiving a baseband rf input signal, and including an up-converter with frequency supplied by an up-converter voltage controlled oscillator, vco; a down-converter with frequency supplied by a down-converter vco; a costas loop sub-module; and baseband outputs from the down-converter to a digital modem circuit. The up-converter feeds the down-converter, and the costas loop module performs costas loop functionality on the output of the down-converter to control the up-converter vco frequency output to thereby control modification of rotation of symbols of the baseband signal..
|Methods of treating sickle cell disease and related disorders using fumaric acid esters|
Methods of using one or more fumaric acid esters or pharmacologically active salts, derivatives, analogues, or prodrugs thereof to increase expression of fetal hemoglobin (hbf) are disclosed. The methods typically include administering to a subject an effective amount of one or more fumaric acid esters optionally in combination or alternation with hydroxyurea to induce hbf expression in the subject in an effective amount to reduce one or more symptoms of a sickle cell disorder, a hemoglobinopathy, or a beta-thalassemia, or to compensate for a genetic mutation is the human beta-globin gene (hbb) or an expression control sequence thereof.
|Batrachotoxin analogues, compositions, uses, and preparation thereof|
Compounds relating to batrachotoxin are provided, in particular analogues that modulate the activity of sodium channels. Also provided are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier, including vehicles that modulate transdermal permeation of the compound.
|Receiver for a telecommunications system|
Methods and apparatus in a near-field communication system, in which a modulated signal received in a reader is clipped by applying upper and lower clip levels. After clipping, the modulated part of the signal corresponds to a greater portion of the overall signal, and thus the requirements placed on an analogue-to-digital converter for the clipped signal are reduced.
|New ligands for targeting of s1p receptors for in vivo imaging and treatment of diseases|
The present invention relates to novel compounds of formulae (i) and (ii) which are useful in the prevention, treatment and diagnosis, in vivo diagnosis of diseases or disorders related to s1p receptors, in particular, in diseases which are connected to the regulatory function of sphingosine-1-phosphate (s1p) and its analogues, such as inflammation, pain, autoimmune diseases and cardiovascular diseases.. .
|Distributed antenna system and method|
A system for the distribution of radio-frequency signals includes a main unit associated with a first radio communication set, a remote unit associated with a second radio communication set installed in a preset area, for radio coverage of the area, and a communication channel associated with the main and remote units, wherein the main unit and remote units have analogue modulation elements of signals to be sent on the communication channel. The remote unit includes a selective amplification unit associated with the second radio communication set and having analogue/digital conversion elements of signals coming from the main unit, through the communication channel, and/or of signals coming from the second radio communication set, digital filtering elements of digital signals coming out of the analogue/digital conversion elements and amplification elements of signals coming from the main unit, through the communication channel, and/or of signals coming from the second radio communication set..
|Receiver and method of receiving|
A receiver receives payload data from a downstream signal, and includes a filter to receive the downstream signal, and including signalling data identifying downstream resources for the payload data, and an analogue to digital converter to receive the downstream signal from the filter and to convert it into a sampled digital form. A demodulator demodulates the digital form of the downstream signal to recover the payload data and the signalling data.
|Synthesis of tetracyclines and analogues thereof|
The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics.
|Treatment with human growth hormone analogues|
The present invention concerns an improved therapeutic regimen for ghd therapy. In particular, the invention concerns methods for bolus dose administration of a human growth hormone-xten (hgh-xten) fusion protein..
|Estimation of resistance in electrical machines|
In an electrical machine which has unidirectional excitation applied to its windings, the mean values of voltage and current can be computed from the instantaneous phase voltage and current by the use of, for example, low-pass filters (in either the analogue or digital domain). The value of winding resistance can then be calculated by dividing the mean voltage by the mean current.
|Biaryl derivatives as nachr modulators|
Disclosed is a compound of formula (i): wherein ‘d’, ‘e’, ‘m’, ‘n’ and r1-r4 are as described herein, as a modulator of nicotinic acetylcholine receptors particularly the α7 subtype, in a subject in need thereof, as well as analogues, prodrugs, isotopically substituted analogs, metabolites, pharmaceutically acceptable salts, polymorphs, solvates, isomers, clathrates, and co-crystal thereof, for use either alone or in combinations with suitable other medicaments, and pharmaceutical compositions containing such compounds and analogues. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and therapy of disorders such as alzheimer's disease, mild cognitive impairment, senile dementia, and the like..
|Alpha-and gamma-msh analogues|
The present invention provides peptide analogues of α-msh and γ-msh, comprising the amino acid sequence of human α-msh or γ-msh, or variants thereof, and having a branched amino acid probe in the n-terminal part of the peptide.. .
|Process for the synchronization of ovulation for timed breeding without heat detection|
A method for synchronizing ovulation in sows and gilts without heat detection by a single injection of hormones is disclosed. A hormone, gonadotropin releasing hormone (gnrh), luteinizing hormone (lh), follicle stimulating hormone (fsh), human chorionic gonadotropin (hcg), analogues, derivatives, agonists or combinations thereof is administered to an open sow post weaning at a specific time to stimulate ovulation of mature responsive follicles.
|Dry blend for making cheese analogue|
Disclosed herein are dry blends used in the process of making cheese analogues with an improved economic profile. Further, the blends disclosed herein may be used to make 100% analogue, vegan, or low-moisture cheeses..
|Selective glucagon-like-peptide-2 (glp-2) analogues|
Glp-2 analogues are disclosed which comprise one of more substitutions as compared to h[gly2]glp-2 and which may have the property of an increased small intestine/colon and stomach/colon selectivity. More particularly, preferred glp-2 analogues disclosed herein comprise substitutions at one or more of positions 11, 16, 20, 24 and/or 28 of the wild-type glp-2 sequence, optionally in combination with further substitutions at position 2 and one or more of positions 3, 5, 7, and 10, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a n-terminal or c-terminal stabilizing peptide sequence.
|Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis c infection|
The present invention relates to novel cyclosporine analogues having antiviral activity against hcv and useful in the treatment of hcv infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds..
|Audio processing device and method|
An audio processing device includes a setting section that sets a reproduction sampling frequency fplay and a recording sampling frequency frec higher than fplay, a digital-to-analogue converter that based on fplay converts a sound source signal that is a digital signal into a reproduction signal that is an analogue signal, an analogue-to-digital converter that based on frec converts a recording signal that is an analogue signal converter into an input signal that is a digital signal, a signal separator that separates the input signal into a low region signal contained in a band of less than fplay and a high region signal contained in a band of the fplay and higher, and a breakup detector that detects whether or not breakup is occurring in the reproduced sound based on power of the high region signal.. .
|Integrated circuit device and method of dynamically modifying at least one characteristic within a digital to analogue converter module|
An integrated circuit device comprises at least one digital to analogue converter module. The dac module includes at least one current replicator component having a first channel terminal, a second channel terminal and a reference voltage terminal arranged to receive a reference voltage signal; the at least one current replicator component being arranged to moderate a current flowing between the first and second channel terminals based at least partly on the received reference voltage signal.
|Electric drive unit|
An electric drive unit includes an electric motor, an inverter supplying electricity to the motor, a continuous current stage supplying electricity to the inverter, a controller including a modulator for driving the inverter controlled by a first digital signal representing the amplitude of the phase voltages to be applied to the motor and by a second digital signal representing the electrical frequency of the phase voltages. An analogue/digital stage calculates the optimum value of the advance angle (δopt) of the voltage applied to the motor relative to the counter-electromotive force (“cemf”) as a linear function of the peak value of the phase current and an analogue/digital stage for measuring the angle (100 act) between the voltage applied to the electric motor and the phase current.
|Semiconductor inks films, coated substrates and methods of preparation|
This invention provides compositions useful for preparing films of czts and its selenium analogues on a coated substrate. This invention also provides processes for preparing films and coated substrates comprising czts/se microparticles embedded in an inorganic matrix.
|Evaluation of resolver sensor signals|
Circuit (2) for evaluating resolver sensor signals (28) in a vehicle, having a resolver sensor (4), set up to pick up a rotary movement of a rotor (6) in an electrical machine (16), and a processor element (12), wherein the resolver sensor (4) is set up to output at least one sinusoidal or cosinusoidal amplitude-modulated analogue signal that is characteristic of the rotary movement of the rotor (6), characterized in that the processor element (12) has a data processing unit (12a), a resolver sensor actuation unit (12b) and a resolver sensor evaluation unit (12c), wherein the analogue signal from the resolver sensor (4) is connected directly to the resolver sensor evaluation unit (12c).. .
|Biodegradable stent formed with polymer-bioceramic nanoparticle composite and method of making the same|
The present invention relates to biodegradable medical devices such as stents manufactured from biodegradable polymeric-bioceramic nanoparticle composites. The invented medical devices include at least one bioceramic nanoparticle dispersed in at least one biodegradable polymer, wherein the said biodegradable polymers include biodegradable polyesters.
|Enzymatic synthesis of carba-nad|
The disclosure concerns the enzymatic synthesis of stable analogues of nicotinamide adenine dinucleotide nad/nadh and nicotinamide adenine dinucleotide phosphate nadp/nadph, the so-called “carba-nads”, i.e. Analogues of nad/nadh or nadp/nadph, respectively, comprising a carbacyclic sugar instead of ribose..
|Cyclosporine analogue mixtures and their use as immunomodulating agents|
The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine a. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives.
|Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators|
The present invention relates to stable compositions comprising a sphingosine 1 phosphate (s1p) receptor modulator, suitable for use as a dosage form. The s1p receptor modulators are typically sphingosine analogues, such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e.g.
|Synthetic rigidin analogues as anticancer agents, salts, solvates and prodrugs thereof, and method of producing same|
Wherein r1 and r2 are selected from hydrogen, aryl, fused aryl, heteroaryl, saturated carbocylclic, partially saturated carbocyclic, saturated heterocyclic, partially saturated heterocyclic, c1-10 alkyl, haloalkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitroalkyl, cyanoalkyl, acetamidoalkyl, and acyloxyalkyl. A process for the preparation thereof is also provided..
|Cyclosporine analogue molecules modified at amino acid 1 and 3|
Analogues of cyclosporin-a are disclosed comprising modifications of the substituents as the positions of amino acids 1 and 3, according to the following formula. The disclosed compounds include compounds having affinity for cyclophilin, including cyclophilin-a, and reduced immunosuppressivity in comparison with cyclosporin-a and analogs thereof modified solely at position 1..
|Reconstituted pulmonary surfactants|
The present invention is directed to a reconstituted surfactant comprising a phospholipid mixture, and a combination of particular analogues of the native surfactant protein sp-c with analogues of the native surfactant protein sp-b. The invention is also directed to pharmaceutical compositions and kits thereof and to its use for the treatment or prophylaxis of rds and other respiratory disorders..
|Fermentation medias and processes thereof|
The present invention demonstrates the utility of carbonic acid amides such as urea or its derivatives, carbamates, carbodiimides & thiocarbamides as nitrogenous supplements in fermentation media for production of recombinant proteins to achieve enhanced bioconversion rates and peptides like insulin and insulin analogues, exendin and enzymes such as lipase using methanol inducible fungal expression systems such as pichia.. .
|Chemically modified cell-penetrating peptides for improved delivery of gene modulating compounds|
The present invention relates to a system for intracellular delivery of a cargo comprising at least one component a chosen from aliphatic linear or branched moieties with at least 4 carbon atoms and/or cyclic ring systems comprising 2-4 rings which may contain several hetero atoms chosen from n, s, o and p, wherein component(s) a is (are) attached to a cell penetrating peptide b and/or a non-peptide analogue thereof. It also relates to methods of using the system in diagnosis of diseases, as research tool and as a targeting system, a composition comprising the system and especially a pharmaceutical composition a material covered with the system and a material having the delivery systems into the material.
|Tin-117m somatostatin receptor binding compounds and methods|
Tin-117m somatoostatin analogues or antagonist are used to treat tumors and symptoms associated with these tumors which express somatostatin receptors, such as gastroenteropancreatic neuroendocrine tumors. The tin-117m somatostatin receptor binding compounds can be administered at a dosage which is effectively apoptotic and not necrotic.
|Calibration of delay chains|
A calibratable delay chain having a delay chain and an adjustment circuitry varying a delay of each of the plurality of delay stages in the chain. The calibration circuitry is configured to calibrate a delay of the delay chain.
|Synthesis of nucleosides|
A process for the preparation of nucleosides, derivatives and analogues thereof by coupling reaction of a protected suitable nitrogeneous purine or pyrimidine base, a derivative or analogue thereof and a protected suitable sugar in the presence of sncl4 comprising the removal of sncl4 by adding dmso directly into the reaction mixture is described. Preferably said process is used for the preparation of antiviral and antitumor agents having a nucleoside or nucleoside-like structure, still more preferably for the preparation of azacytidine, decitabine, chlorfarabine, cladribine, mizoribine.
|Diagnosis and treatment of friedreich's ataxia|
The present invention is directed to oligonucleotides based on peptide nucleic acid oligonucleotide or an equivalent oligonucleotide analogue, such as morpholino or a locked nucleic acid sequences and the use of such oligonucleotides for the dissociation of higher order structures, including triplex-helix dna structures, in repeated sequences of dna in friedreich's ataxia. The dissociation of such structures may be used in the diagnosis and/or treatment of friedreich's ataxia.
|Insulin analogues containing penta-fluoro-phenylalanine at position b24|
An insulin analogue comprises a b-chain polypeptide incorporating a halogenated phenylalanine at position b24, b25 or b26. The halogenated phenylalanine may be ortho-monofluoro-phenylalanine, ortho-monobromo-phenylalanine, ortho-monochloro-phenylalanine, or para-monochloro-phenylalanine or penta-fluoro-phenylalanine at position b24 alone or in combination with an acidic substitution (aspartic acid or glutamic acid) at position b10.
|Encoded self-assembling chemical libraries (esachel)|
The invention concerns a chemical compound comprising a chemical moiety (p) capable of performing a binding interaction with a target molecule (e.g. A biological target) and further comprising an oligonucleotide (b) or functional analogue thereof.
|Fagopyritol synthase genes and uses thereof|
The present invention relates to an isolated dna molecule encoding a fagopyritol synthase. A method for producing a fagopyritol, an insulin mediator, an insulin mediator analogue, an insulin mediator homologue, or an insulin mediator inhibitor is also described.
|Stabilization of battery electrodes using polymer coatings|
An electrochemical device (e.g., a battery (cell)) including: an aqueous electrolyte and one or two electrodes (e.g., an anode and/or a cathode), one or both of which is a prussian blue analogue material of the general chemical formula axp[r(cn)6-jlj]z.nh2o, where: a is a cation; p is a metal cation; r is a transition metal cation; l is a ligand that may be substituted in the place of a cn− ligand; 0≦x≦2; 0≦z≦1; and 0≦n≦5, the electrode including a polymer coating to reduce capacity loss.. .
|Stabilization of battery electrodes|
An electrochemical apparatus (e.g., a battery (cell)) including an aqueous electrolyte with electrode stabilizing additives and one or two electrodes (e.g., an anode and/or a cathode), one or both of which is a prussian blue analogue material of the general chemical formula axp[r(cn)6-jlj]z.nh2o, where: a is a cation; p is a metal cation; r is a transition metal cation, l is a ligand that may be substituted in the place of a cn− ligand; 0≦x≦2; 0≦z≦1; and 0≦n≦5 with the electrolyte including an additive to reduce capacity loss of the electrode(s).. .
|Stabilization of battery electrodes using prussian blue analogue coatings|
An electrochemical apparatus (e.g. A battery (cell)) including an aqueous electrolyte and one or two electrodes (e.g., an anode and/or a cathode), one or both of which includes a prussian blue analogue (pba) material of the general chemical formula axp[r(cn)6-jlj]z.nh2o, where: a is a cation; p is a metal cation; r is a transition metal cation; l is a ligand that may be substituted in the place of a cn− ligand; 0≦x≦2; 0≦z≦1; and 0≦n≦5, one or both electrodes including a pba coating to decrease capacity loss..
|Synthetic scfv analogue to the 6313/g2 (anti angiotensin ii type 1 receptor) monoclonal antibody variable regions|
The present invention provides a specific binding molecule which specifically binds to a peptide having the amino acid sequence of edgikriqdd and comprises a polypeptide having an immunoglobulin vl domain linked to an immunoglobulin vh domain in which the vl domain comprises complementarity determining regions (cdrs) vlcdr1, vlcdr2 and vlcdr3, and in which the vh domain comprises complementarity determining regions (cdrs) vhcdr1, vhcdr2, vhcdr3, each having a respective amino acid sequence as follows in which vhcdr1 is gysftgynmn vhcdr2 is nidpyyggttynqkfkg vhcdr3 is evdy vlcdr1 is rasksvststsgysymh vlcdr2 is lvsnles vlcdr3 is qhireltrseg or an amino acid sequence at least 70% identical thereto.. .
The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods.
The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods.
|Insulin analogues of prolonged activity|
New biosynthetic analogues of recombined human insulin of prolonged therapeutical activity, which can find place in prophylactic and treatment of diabetes.. .
The present invention relates to dipeptide enkephalin analogues of formula (i) and their tautomers, ionic forms and pharmaceutically acceptable salts, and their use in medicine, in particular as opioid agonists.. .
|Thiol mediated/activated prodrugs of sulfur dioxide (so2) having anti-bacterial activity|
Disclosed herein are thiol mediated/activated prodrugs of so2, particularly 2,4-dinitrophenylsulfonamide analogues, having formula-i or pharmaceutically acceptable salts thereof exhibiting tunable release profiles of so2 with significant therapeutic efficacy against bacterial infections. Further, the present invention provides pharmaceutical compositions comprising compound of formula i or pharmaceutically acceptable salts thereof, along with pharmaceutically acceptable carriers/excipients..
|Prevention of kidney injury or disease|
The present invention relates to a dosage regime of a peptide analogues of [alpha]-melanocyte-stimulating hormone ([alpha]-msh), which possesses an increased efficacy compared to the native [alpha]-msh peptide in the treatment or prevention of kidney injury or disease.. .